TELA Bio to Participate in Three Upcoming Conferences

Rhea-AI Summary

MALVERN, Pa., Nov. 08, 2021 - TELA Bio, Inc. (NASDAQ: TELA) announced its participation in key healthcare conferences, including the Canaccord Genuity MedTech Forum, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference. Management will present on November 18 and 22, 2021. These events focus on TELA's innovative tissue reinforcement materials aimed at improving outcomes in soft tissue reconstruction. Live webcasts will be accessible for stakeholders.

MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, 12^th Annual Jefferies London Healthcare Conference, and the 33^rd Annual Piper Sandler Healthcare Conference.

TELA Bio's management is scheduled to present at the following;

• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021 at 11:30 AM EST
  
  
• The 12^th Annual Jefferies London Healthcare Conference and the pre-recorded fireside chat will be available beginning Thursday, November 18, 2021 at 8:00 AM GMT
  
  
• The 33^rd Annual Piper Sandler Healthcare Conference and the pre-recorded fireside chat will be available beginning Monday, November 22, 2021 at 10:00 AM EST
  

Interested parties can access the live and archived webcasts at ir.telabio.com.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
347-620-7010 
ir@telabio.com

FAQ

When will TELA Bio participate in the Canaccord Genuity MedTech Forum?

TELA Bio will participate in the Canaccord Genuity MedTech Forum on November 18, 2021 at 11:30 AM EST.

What key conferences is TELA Bio attending in November 2021?

TELA Bio is attending the Canaccord Genuity MedTech Forum, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference in November 2021.

Where can I watch TELA Bio's conference presentations?

You can watch TELA Bio's conference presentations live and archived at their investor relations website.

What products does TELA Bio focus on?

TELA Bio focuses on designing and marketing innovative tissue reinforcement materials for soft tissue reconstruction.

What is TELA Bio's mission?

TELA Bio aims to provide advanced biologic material repair solutions to improve clinical outcomes in soft tissue reconstruction.